Bhutani Divaya, Zonder Jeffrey A
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA,
Blood Lymphat Cancer. 2017 Jul 19;7:53-60. doi: 10.2147/BLCTT.S82444. eCollection 2017.
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myeloma. Carfilzomib is a second-generation proteasome inhibitor with irreversible binding to proteasome and less off-target toxicity. The drug has been approved for use in relapsed/refractory multiple myeloma. In this article, we review the use of carfilzomib as second-line therapy in multiple myeloma. We also review the current standards of care for relapsed/refractory multiple myeloma, with particular focus on the use of carfilzomib in advanced disease.
蛋白酶体抑制剂的研发是多发性骨髓瘤治疗领域的一项重大进展，部分促成了被诊断为此病的患者生存率的显著提高。硼替佐米是首个被批准用于治疗多发性骨髓瘤的蛋白酶体抑制剂。卡非佐米是第二代蛋白酶体抑制剂，与蛋白酶体不可逆结合且脱靶毒性较低。该药物已被批准用于复发/难治性多发性骨髓瘤。在本文中，我们回顾了卡非佐米作为多发性骨髓瘤二线治疗药物的应用情况。我们还回顾了复发/难治性多发性骨髓瘤的当前治疗标准，尤其关注卡非佐米在晚期疾病中的应用。
